Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report 2026

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

• Duchenne Muscular Dystrophy (DMD) Therapeutics market size has reached to $16.38 billion in 2025 • Expected to grow to $62.13 billion in 2030 at a compound annual growth rate (CAGR) of 30.5% • Growth Driver: Rise In Clinical Trials Fueling The Growth Of The Market Due To Increasing Demand For Innovative Treatment Evaluation • Market Trend: Bit Bio Leads Technological Advancements In Duchenne Muscular Dystrophy (DMD) Therapeutics • North America was the largest region in 2025.

What Is Covered Under Duchenne Muscular Dystrophy (DMD) Therapeutics Market?

Duchenne muscular dystrophy (DMD) therapeutics refers to the various medical treatments and interventions aimed at managing and alleviating the symptoms of duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle weakness and degeneration. These therapeutic approaches are designed to slow disease progression, improve muscle function and enhance the overall quality of life for individuals with duchenne muscular dystrophy. The main types of duchenne muscular dystrophy (DMD) therapeutics are small molecules and biologics. Small molecules are low-molecular-weight compounds that can interact with specific proteins or targets in the body and they can be designed to target specific aspects of DMD, such as reducing inflammation, promoting muscle regeneration, or addressing specific genetic mutations. Therapeutics are distributed through offline and online channels for applications in hospitals, clinics and home care.

What Is The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Forecast?

The duchenne muscular dystrophy (dmd) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $62.13 billion in 2030 at a compound annual growth rate (CAGR) of 30.5%. The growth in the forecast period can be attributed to advances in gene therapy, growing investment in precision medicine, technological integration in patient monitoring, expansion of biologics manufacturing, increased collaboration between pharma and biotech companies. Major trends in the forecast period include personalized therapeutic development, gene editing and gene therapy advancements, novel drug delivery systems, orphan drug market expansion, patient-centric care models.

What Is The Driver Of The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?

The rising number of clinical trials is expected to propel the growth of the Duchenne muscular dystrophy (DMD) therapeutics market going forward. Clinical trials are research studies conducted on human participants to evaluate the safety, efficacy and potential benefits of new medical treatments, interventions, or drugs. Clinical trials are increasing due to the growing demand for innovative therapies that address unmet medical needs. Duchenne muscular dystrophy (DMD) therapeutics are tested in clinical trials to evaluate their ability to slow disease progression and improve muscle function in patients. For instance, in April 2025, according to the report published by the NLM (National Library of Medicine), US-based government agency, reported that 27,751 interventional clinical trials were initiated in 2023. Therefore, rising number of clinical trials will drive the growth of the Duchenne muscular dystrophy (DMD) therapeutics industry.

Key Players In The Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market

Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Exonics Therapeutics Inc., Wave Life Sciences Ltd., MeiraGTx Holdings plc, Editas Medicine Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc, CRISPR Therapeutics AG, Akouos Inc., Audentes Therapeutics Inc., Stoke Therapeutics Inc., Astellas Pharma Inc., Translate Bio Inc., Ultragenyx Pharmaceutical Inc.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends and Insights

Major companies operating in the duchenne muscular dystrophy (DMD) therapeutics market are adopting new technologies to enhance the efficacy and accessibility of treatments for DMD patients and sustain their position in the market. For instance, in July 2023, Bit Bio Ltd., a UK-based synthetic biology company, launched disease model products to advance Duchenne muscular dystrophy (DMD) treatments. The disease models, known as ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes carrying genetically engineered deletions in the gene responsible for dystrophin protein production. Bit. Bio's models, reprogrammed from induced pluripotent stem cells (iPSCs), provide a consistent and scalable source of human cells for research, addressing challenges associated with variability and the sourcing of primary cells. The models support the development of treatments for DMD, offering insights into disease mechanisms and potential therapies. This advancement could accelerate the work of researchers seeking effective treatments for DMD.

What Are Latest Mergers And Acquisitions In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?

In November 2024, Novartis AG, a Switzerland based pharmaceuticals company, acquired Kate Therapeutics Inc. for $1.1 billion. With this acquisition, Novartis aimed to expand its neuromuscular disease franchise by integrating Kate’s preclinical AAV based gene therapy programs targeting Duchenne muscular dystrophy (DMD) and other muscle disorders. Kate Therapeutics is a US-based biotechnology company that specializes in next-generation gene therapy candidate for DMD using novel capsid and gene regulation technologies.

What Defines the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?

The duchenne muscular dystrophy (DMD) therapeutics market includes revenues earned by entities by providing services including gene therapies, genetic testing and counseling, telehealth and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The duchenne muscular dystrophy (DMD) therapeutics market also include sales of casimersen, eteplirsen and golodirsen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report 2026?

The duchenne muscular dystrophy (dmd) therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the duchenne muscular dystrophy (dmd) therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.